Abstract
Dr Blister is evaluating Mrs M, a 70-year-old woman with recalcitrant mucous membrane pemphigoid. Mrs M’s disease has progressed despite numerous courses of traditional systemic immunosuppressives. She has recently developed bilateral symblepharon. In reviewing her treatment history, Dr Blister realizes that Mrs M has never undertaken a trial of the anti-CD20 infusible agent, rituximab, which has demonstrated efficacy against mucous membrane pemphigoid in small trials. Dr Blister enthusiastically offers the therapy to Mrs M, to which she replies, ‘‘That sounds great, doc, but what are the risks?’’
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
